Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Expands By 201.3%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 49,919 shares, an increase of 201.3% from the June 15th total of 16,568 shares. Based on an average daily trading volume, of 468,461 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $13.22 on Wednesday. The firm’s 50 day moving average price is $13.72 and its 200-day moving average price is $14.65. Astellas Pharma has a twelve month low of $9.46 and a twelve month high of $17.35. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $23.92 billion, a PE ratio of 12.31 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. Equities research analysts expect that Astellas Pharma will post 1.25 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).